Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
Authors: Ashish Sarraju, MDa ∙ Danielle Brennan, MSa ∙ Kierstyn Hayden, MPHa ∙ Amanda Stronczek, MPHb ∙ Prof Anne C Goldberg, MDc ∙ Prof Erin D Michos, MD MHSd ∙ Prof Darren K McGuire, MDe ∙ Denise Mason, BSNa ∙ Grace Tercek, MSa ∙ Prof Stephen J Nicholls, MBBS PhDf ∙ Douglas Kling, MBAb ∙ Annie L Neild, PhDb ∙ John Kastelein, MD PhDb ∙ Michael Davidson, MDb ∙ Marc Ditmarsch, MDb ∙ Prof Steven E Nissen, MD
Journal: The Lancet
Volume 405, Issue 10491
p1757-1768
May 17, 2025
|
30
https://www.sciencedirect.com/journal/precambrian-research/vol/303/suppl/C
